Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC105P in previously treated advanced malignant pleural mesothelioma
ACTRN12610000093088Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BNC105P in pleural mesothelioma, sponsored by University of Sydney. Primary endpoint: Objective tumour response rate. Started Jul 2010; status: completed.
02
Drugs
BNC105P
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ACTRN12610000093088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000093088.